Zheng Hua-Chuan, Xue Hang, Zhang Cong-Yu, Shi Kai-Hang, Zhang Rui
Department of Oncology, The Affiliated Hospital of Chengde Medical University, Chengde, China.
Cancer Center, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou, China.
Front Genet. 2022 Sep 16;13:1006582. doi: 10.3389/fgene.2022.1006582. eCollection 2022.
B cell transposition gene 3 (BTG3) is reported to be a tumor suppressor and suppresses proliferation and cell cycle progression. This study aims to analyze the clinicopathological and prognostic significances, and signal pathways of mRNA expression in human beings through bioinformatics analysis. We analyzed expression using Oncomine, TCGA (the cancer genome atlas), Xiantao, UALCAN (The University of ALabama at Birmingham Cancer data analysis Portal) and Kaplan-Meier plotter databases. Down-regulated expression was observed in lung and breast cancers, compared with normal tissues ( < 0.05), but not for gastric and ovarian cancer ( < 0.05). The methylation of was shown to be adversely correlated with its mRNA expression ( < 0.05). expression was higher in gastric intestinal-type than diffuse-type carcinomas, G than G carcinomas ( < 0.05), in female than male cancer patients, T than T, and adenocarcinoma than squamous cell carcinoma of lung cancer ( < 0.05), in invasive ductal than lobular carcinoma, N than N and N, TNBC (triple-negative breast cancer) than luminal and Her2+, and Her2+ than luminal cancer of breast cancer ( < 0.05), and G than G ovarian carcinoma ( < 0.05). expression was positively related to the survival rate of gastric and ovarian cancer patients ( < 0.05), but not for breast cancer ( < 0.05). KEGG and PPI (protein-protein interaction) analysis showed that the was involved in cell cycle and DNA replication, digestion and absorption of fat and protein, spliceosome and ribosome in cancer. expression was positively linked to carcinogenesis, histogenesis, and aggressive behaviors, and was employed to evaluate the prognosis of cancers by regulating cell cycle, metabolism, splicing and translation of RNA.
据报道，B细胞转位基因3（BTG3）是一种肿瘤抑制因子，可抑制细胞增殖和细胞周期进程。本研究旨在通过生物信息学分析，分析人类mRNA表达的临床病理意义、预后意义及信号通路。我们使用Oncomine、TCGA（癌症基因组图谱）、仙桃、UALCAN（阿拉巴马大学伯明翰分校癌症数据分析门户）和Kaplan-Meier绘图仪数据库分析了BTG3的表达。与正常组织相比，在肺癌和乳腺癌中观察到BTG3表达下调（P<0.05），但在胃癌和卵巢癌中未观察到（P<0.05）。BTG3的甲基化与其mRNA表达呈负相关（P<0.05）。在胃肠型癌中BTG3表达高于弥漫型癌，在G1期癌中高于G2期癌（P<0.05），在女性癌症患者中高于男性，在T1期高于T2期，在肺癌腺癌中高于鳞状细胞癌（P<0.05），在浸润性导管癌中高于小叶癌，在N1期高于N0期和N2期，在三阴性乳腺癌（TNBC）中高于管腔型和Her2+型，在乳腺癌Her2+型中高于管腔型癌（P<0.05），在卵巢癌G1期高于G2期（P<0.05）。BTG3表达与胃癌和卵巢癌患者的生存率呈正相关（P<0.05），但与乳腺癌患者的生存率无关（P<0.05）。KEGG和PPI（蛋白质-蛋白质相互作用）分析表明，BTG3参与癌症中的细胞周期和DNA复制、脂肪和蛋白质的消化吸收、剪接体和核糖体。BTG3表达与肿瘤发生、组织发生和侵袭性行为呈正相关，并通过调节细胞周期、代谢、RNA剪接和翻译来评估癌症的预后。
